Please use this identifier to cite or link to this item:

Title: Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected HealthcareWorkers
Authors: Algarate, Sonia ORCID SCOPUSID
Serrano Barcos, Laura ORCID
Bueno, Jessica ORCID
Alvarado, Elena
Gonzalez-Barriga, Maria T.
Ducons, Maria
Montero-Marco, Jesica
Arnal, Sara
Acha, Beatriz
Riesgo, Maria
Taboada, Ana
Sanz-Burillo, Pilar
Yuste, Cristina ORCID
Keywords: SARS-CoV-2; Booster vaccine; Post-vaccine IgG antibody persistence
Issue Date: 27-Jun-2023
Citation: Algarate, S.; Serrano, L.; Bueno, J.; Herrero-Cortina, B.; Alvarado, E.; González-Barriga, M.T.; Ducons, M.; Montero-Marco, J.; Arnal, S.; Acha, B.; et al. Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected HealthcareWorkers. Int. J. Mol. Sci. 2023, 24, 10713. https://
Abstract: Our aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of the RIPOVAC study, between December 2021 and January 2022, eight months after the second dose, 389 voluntary, immunocompetent, non-pregnant healthcare workers received a booster dose of SARS-CoV-2 vaccine, and a serum sample was obtained. Two groups of patients were established: with and without previous SARS-CoV-2 infection. In order to quantify anti-S1 IgG (AU/mL) we used CMIA (Abbott). All of the health workers were anti-S IgG positive 8 months after receiving the booster dose of the vaccine, with a mean of 17,040 AU/mL. In 53 patients without previous infection, antibody levels increased by a mean of 10,762 AU/mL. This figure is seven times higher than the one produced after the second dose (1506 AU/mL). The booster dose produces a robust elevation of the antibody level, which persists at 8 months, with levels significantly higher than those reached after the second dose, which allow one to predict a persistence of more than one year. The study demonstrates the efficacy of the booster dose of anti-SARS-CoV-2 vaccines.
ISSN: 1661-6596
Appears in Collections:Artículos de revistas

Files in This Item:
File Description SizeFormat 
Persistence of Anti-S1 IgG against SARS-CoV-2.pdf927,39 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons